Palazestrant
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.
Product Specifications
CAS Number
2092925-89-6
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
449.6
Molecular Formula
C28H36FN3O
Notes
Research use only, not for human use.
Receptor
Estrogen/progestogen Receptor
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1428744-01 0.02 mg (E-Coli)
Recombinant Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase (murE)
Sign In for Pricing
View Details MBS1428744-02 0.02 mg (Yeast)
Recombinant Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase (murE)
Sign In for Pricing
View Details MBS1428744-03 0.1 mg (E-Coli)
Recombinant Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase (murE)
Sign In for Pricing
View Details MBS1428744-04 0.1 mg (Yeast)
Recombinant Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase (murE)
Sign In for Pricing
View Details MBS1428744-05 0.02 mg (Baculovirus)
Recombinant Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase (murE)
Sign In for Pricing
View Details